The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

Carhart-Harris, Robin L, Goodwin, Guy M·2017·Neuropsychopharmacology
DOI 10.1038/npp.2017.84

Cited by (702)

Items 601–700 of 702

  1. Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report
    M Mercier, Cédric Mabilais, Vasileios Chytas, Leonice Furtado, Federico Seragnoli, Albert Buchard, Tatiana Aboulafia Brakha, Gabriel Thorens, DANIELE FABIO ZULLINO, Louise E. Penzenstadler · 2025 · Psychoactives
  2. Behavioural investigations of psilocybin in non-human animals 1962–2021: A scoping review
    Ron Shore, K. Dobson, Nina Thomson, Nigel Barnim, Hailey P Bergman, Katie Rideout, Sandra McKeown, Mary C. Olmstead, Craig E. Goldie, Éric C. Dumont · 2025 · Journal of Psychedelic Studies
  3. Research progress in ionic liquids-gel electrolytes for electrochromism
    Jianing Wang, Guodong Liu, Xiaohong Jiang, Junkai Wu, Hanbin Liu, Wenliang Zhang, Zhijian Li · 2025 · Scientia Sinica Chimica
  4. Advancements in psychedelic research: Effects, mechanisms, and therapeutic potential as emerging antidepressants
    Xianqiang Zhang, De-Nong Liu, Qing-Shan Miao, Xu Cai, Lu-Xin Zong, Yu-Kun Hou, Jing Xiong · 2025 · Pharmacology Biochemistry and Behavior
  5. Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders
    John L. Havlik, Sayana Isaac, Pralahad Raman, Nathan Tran, Kalea Hidalgo, Trisha M Suppes · 2025 · Journal of Clinical Psychopharmacology
  6. A Look to “Classical” Psychedelics and the Atypic Dissociative Ketamine: Some Basics for Approaches to Medical Conditions
    Sabine Himmelseher, Ulrike Vogelmann, Josef Priller · 2025 · Neuromethods
  7. Ethical challenges in the therapeutic application of classical psychedelics for pediatric health conditions: A comprehensive review
    Pinelopi Vlotinou, Konstantinos Christodoulou, Anna Tsiakiri, Foteini Christidi, Aspasia Serdari · 2025 · Brazilian Journal of Science
  8. Deleuze’s crystal-image, the Anthropocene, and education
    David Robert Cole · 2025 · Research in Education
  9. Psychedelics and Mysticism: Mapping Cultural Approaches
    Tatiana Tiaynen-Qadir · 2025 · Springer eBooks
  10. Entheogens
    Rita M. Rivera · 2025 · Springer eBooks
  11. A Comparative Neurophenomenology of the Psychedelic State and Autism: Predictive Processing as a Unifying Lens
    William Roseby, Catriona Osborn Moar · 2025 · Psychoactives
  12. Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review
    Jacques Suspène, Sarah Huet, Sabine Berteina‐Raboin, Amine Benyamina, Patrick Baril, Séverine Morisset‐Lopez, Raphaël Serreau · 2025 · Qeios
  13. Standing in the Gap: Psychedelic Advocacy, Communities of Color, and the Politics of Knowledge Production
    Tina Kempin Reuter, Fanicy Sears, Lisa L. Gezon · 2025 · Anthropology of Consciousness
  14. The Potential Therapeutic Effects of MEAI in the Treatment of Alcohol Use Disorder
    Mahna Ekhlasi, Angerlyk Frytz, Anahita Bassir Nia · 2025 · Current Addiction Reports
  15. Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review
    Jacques Suspène, Sarah Huet, Sabine Berteina‐Raboin, Amine Benyamina, Patrick Baril, Séverine Morisset‐Lopez, Raphaël Serreau · 2025 · Qeios
  16. Towards therapeutic paths with mindfulness meditation–based and psychedelics assisted psychotherapies in PTSD: Randomized controlled trials systematic review and meta-analysis
    Solène Maeder, Chérine Fahim, Chantal Martin-Söelch · 2025 · Cortica
  17. Effects of LSD and Psilocybin on Heart Rate in Patients Receiving Psychedelic Treatment for Depressive and Anxiety Disorders: A Retrospective Observational Study
    Mylène Cheng, Tatiana Aboulafia Brakha, Albert Buchard, Raya Anastasova, Léa Girani, Anna Breitenmoser, Sylvie Alaux, Cédric Mabilais, Caroline Amberger, Federico Seragnoli et al. · 2025 · Psychology International
  18. ‘Shrooms for the Blues: Psilocybin to alleviate difficult-to-treat depression
    Zoe Graham · 2022 · Journal of High School Science
  19. Additional file 1 of Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health
    Rebecca S. Ryan, Copello, Alex, Andrew P. Fox · 2024 · Figshare
  20. Medicinal Mushrooms and Mental Disorders: How Mushrooms Affect Anxiety and Depression
    Anahita Tarki, Arman Hajikarim‐Hamedani, Setareh Rassa, Sepehr Khosravi · 2025 · Nutritional neurosciences
  21. Psychedelics and Respiratory Health: A Literature Review
    Manal Muteb Alanazi, Mohammed Μ. Alqahtani · 2025 · Psychedelic Medicine
  22. Mushrooms to Avoid
    Asifa Kausar, Khadija Javed, Muhammad Zaid Salar, Naila Ghafoor, Quratulann Sattar, Amara Tahir, Ayesha Ghafoor, A. FAROOQ · 2025 · Springer eBooks
  23. Violence and Mental Illness: Principles, Pathways, and Perspectives of Peril
    2026 · FOCUS The Journal of Lifelong Learning in Psychiatry
  24. Serendipity in psychiatric discoveries: historical lessons and future imperatives for clinical observation
    Stanley Lyndon, Vineeth P. John · 2026 · BJPsych Bulletin
  25. Contextualizing Violence Risk Associated With Hallucinogens
    Tyler A. Durns, Greg Iannuzzi · 2026 · FOCUS The Journal of Lifelong Learning in Psychiatry
  26. Altered States of Consciousness Modulate Aesthetic Processing in Naturalistic Art Viewing
    Erdem Taskiran, Tomaso Gazzola, Andrea Polo, Andrea Signorelli, Nicola De Pisapia · 2026 · SSRN Electronic Journal
  27. Can LLMs Get High? A Dual-Metric Framework for Evaluating Psychedelic Simulation and Safety in Large Language Models
    Ziv Ben‐Zion, Guy Simon, Teddy Lazebnik · 2026 · Research Square
  28. Metamodernism and Psychedelics: The good, the bad, and the ugly
    Michael R. Montgomery, Noah Cebuliak · 2026 · Existential Analysis Journal of the Society for Existential Analysis
  29. Hallucinogenic Therapy in Alzheimer’s Disease targeting Mitochondria-Associated Membranes
    Fernando Minauro‐Sanmiguel, Héctor Vargas-Pérez · 2026 · Neuroscience
  30. Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
    Målin Schmidt, Anne Hoffrichter, Mahnaz Davoudi, Sandra Horschitz, Thorsten Lau, Marcus W. Meinhardt, Rainer Spanagel, Julia Ladewig, Georg Köhr, P J Koch · 2026 · eLife
  31. Predictors of the Effectiveness of Psychedelics in Treating Depression—A Scoping Review
    James Chmiel, Filip Rybakowski · 2026 · International Journal of Molecular Sciences
  32. The combination of exercise and psychedelics for the treatment of major depressive disorder
    Nicholas Fabiano, Brendon Stubbs, David Wyndham Lawrence, Joshua Daniel Rosenblat, Pedro J. Teixeira, Stanley Wong, Carl Zhou, Robin Lester Carhart-Harris · 2026 · Discover Mental Health
  33. Confronting mortality: A meta-analysis and systematic review of psychedelic experiences and death anxiety
    Alicia Cohorst, Petri Kajonius · 2026 · Journal of Psychopharmacology
  34. Age moderates the relationship between psychedelics use and mental health in naturalistic settings
    Giammarco Di Gregorio, Basset Sophia, Harjot Manmohan, Warren C. Nixon, Amrutha Pogaku, Jing Zhou, David J. Sanderson, Michael L. Lengieza, Marco Bocchio · 2026 · Research Square
  35. A neurocognitive account of complex PTSD: self-modelling, affective dysregulation, and implications for MDMA-assisted and targeted psychotherapies
    Philip Gerrans, Hugh T. McGovern, Jakob Hohwy, Lena Oestreich · 2026 · European Journal of Psychotraumatology
  36. Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil
    Marina A. M. Portes, Leandro Jose Bertoglio · 2026 · Journal of Psychoactive Drugs
  37. Psilocybin: Chemical Foundations and Emerging Therapeutic Potential
    Shivaputra A. Patil, Holly C. Hunsberger · 2026 · Mini-Reviews in Medicinal Chemistry
  38. Psychedelics; an untapped therapeutic niche: a narrative review in the future of cancer pain management
    Maxine Min Chien Yap, Yasir Marwan Abdalla Omer, Yu Xuan Cheng, Wei Qi Chan, Satoshi Ogawa · 2026 · Medicine in Drug Discovery
  39. “I can objectively view my trauma without feeling like I'm there”: Reddit discussions on self-reported use of psychedelics to address co-occurring substance use and mental health needs
    Emma Yuanqi Gu, Natalia M. Irvine, Megan Jo Miller, Elisbel Ramirez, Julián Santaella-Tenorio, Thomas Lippincott, Michael P. Bogenschutz, Amanda M. Bunting, Meredith C. Meacham, Noa Krawczyk · 2026 · Journal of Psychedelic Studies
  40. Psychedelics in mental healthcare show growing interest but uneven evidence
    Maria Sarang, Riccardo De Giorgi · 2026 · BMJ
  41. MDMA-assisted therapy for PTSD and Substance Use Disorders: A Scoping Review of Feasibility and Future Directions
    Teun L. Meijer, Amras van Opdorp, Wiebren Markus · 2026 · Psychedelics
  42. Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use
    Kush V. Bhatt, Joseph Friedman, Lindsay L. Benster, Rekha Narasimhan, Kevin Yang, Jyoti Mishra, Cory R. Weissman, Dhakshin Ramanathan · 2026 · Community Mental Health Journal
  43. Médicament ou poison ? : médecins, médecine et psychotropes de la fin du XIXe siècle à nos jours en France
    Zoë Dubus · 2022
  44. Perceptions of Australasian palliative care physicians regarding the safety and efficacy of psychedelic medicines: An exploratory mixed-methods study
    Nicholas Sawers, Michael Billingsley, David Benjamin Menkes · 2026 · Psychedelics
  45. Psilocybin and Other Psychedelic Compounds
    Siena M Madsen, J Andrew Jones · 2026 · Elsevier eBooks
  46. Une enquête philosophique sur les modèles animaux : des questions fondamentales à la modélisation et aux traitements des pathologies psychiatriques
    Héloïse Athéa · 2024
  47. Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications
    Shakila Meshkat, Manish K. Jha, Venkat Bhat · 2026 · FOCUS The Journal of Lifelong Learning in Psychiatry
  48. Resetting the default in the psychedelic renaissance
    Sujit T. Thomas · 2026 · BioSocieties
  49. The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes
    Mohsen Khosravi, Domenico De Berardis, Massimo Tusconi · 2026 · Mental Wellness
  50. Ecology and Diversity of Edible and Medicinal Mushrooms Across Different Habitats
    José Maria Correia da Costa, Maria Teresa Queiros dos Santos, Raquel P. F. Guiné · 2026 · Springer eBooks
  51. "Riding the Wave"—Social Work Roles in Psychedelic Therapy Settings: A Scoping Review
    Abel Walker, Stacey R. Kolomer, Kristin W. Mapson · 2026 · Clinical Social Work Journal
  52. Psychedelic Use and Psychological Healing Among Gender Exploring Clients: Clinicians’ Perspectives
    Esenia K. Cassidy, Juliana Riccardi, Britt Healy, Sree Sushma Monika Golakoti, Panteá Farvid · 2026 · Women & Therapy
  53. Community, credibility, and care: Activist public relations in the Portuguese psychedelic field
    Naíde Müller · 2026 · Public Relations Inquiry
  54. Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USA
    R Andrew Yockey, Amber Amis, Elise Devier, Aminul I. Apu, Rachel A. Hoopsick · 2026 · AJPM Focus
  55. Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat
    Joanna Kuc, Rosalind G. McAlpine, Amelia Sellers, George Blackburne, Daniel Robert Lametti, Jeremy I Skipper · 2026 · Journal of Psychopharmacology
  56. Reframing distress in oncology: the potential of psychedelic-assisted therapy
    Fatima Zohra Moujahid, Olivier Taymans · 2026 · Current Opinion in Oncology
  57. Classic psychedelics and personality: An updated systematic review
    Anna Beatriz Vicentini, Caio Cesar de Paula, José Augusto Silva Reis, José Carlos Bouso, Jaime E. C. Hallak, RAFAEL GUIMARÃES DOS SANTOS · 2026 · Journal of Psychopharmacology
  58. Approaches to ketamine-assisted couple therapy
    David O. Avruch · 2026 · Frontiers in Psychology
  59. Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticity
    Samaneh Ahmadian-Moghadam, Shiva Roshan‐Milani, Ehsan Saboory · 2026 · Translational Psychiatry
  60. EEG microstate dynamics during psilocybin intoxication relate to acute experience and persisting psychological changes
    Nikola Jajcay, Čestmír Vejmola, Jakub Korčák, Filip Tylš, Michaela Viktorinová, Vojtěch Viktorin, Anna Bravermanová, Renata Androvičová, Balíková, Marie,, Jiřı́ Horáček et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  61. Le potentiel psychothérapeutique des états non ordinaires de conscience dans les épisodes dépressifs : une revue de questions
    Claude Berghmans, Aude Monciino · 2026 · L Évolution Psychiatrique
  62. THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY
    Julia Osipowska, Marlena Kwolek, Alicja Judzińska, Bartosz Piech, Kamila Sobczyńska, Justyna Ignarska, Magda Terbosh, Sabina Kubicz `Mzabi, Emilia Trojanowska, Magdalena Dubaj · 2026 · International Journal of Innovative Technologies in Social Science
  63. The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential
    Pavan S. Brar, Rebecca B. Price, Stephen Ross, Babak Tofighi, Deepak K. Sarpal · 2026 · Journal of Psychopharmacology
  64. Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations
    Cielo Amelia Estela-Fernandez, Reem Mohamed Yousif Elsheikh, D F Beatrice, Abdullah A. Alhendal, Chinonso Irene Ewe, Sebastian Y. Montesinos, Jocelyn Wensel, Anushka P Mishra, Asma Ahmed Yousif, Hossam Tharwat Ali · 2026 · Neuropsychiatrie
  65. Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit–Risk Considerations in Policy and Clinical Development
    Stefanie Enriquez‐Geppert, Lisa Bevers, Arvid Rosander, Peter Fodran, Vince Polito · 2026 · Biomolecules
  66. The Evolution of Psychedelics and Psychedelic-Assisted Therapy
    Gurjot Brar, Kevin Lally, John Richard Kelly, Henry P. O'Connell · 2026 · Springer eBooks
  67. Psychedelic-Assisted Psychotherapy Education at GSPP: Assessing PsyD Student and Alumni Interest, Attitudes, and Perceived Training Needs
    Devon Seelig · 2026
  68. Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder
    Robert F. Dougherty, Nadav Liam Modlin, Niall M. McGowan, Patrick C. Staples, Ella Williams, Patrick Clarke, Mario Shafiei, Carly Leininger, Merve Alti, Megan Croal et al. · 2026 · Journal of Psychopharmacology
  69. What About Psycholytic Therapy? A Historical Revisiting of Psychedelics Assisting Psychotherapy
    Idir Zaher, Jérémie Richard · 2026 · Psychedelic Medicine
  70. Consommation illicite de psychédéliques classiques et suicidalité : une revue systématique de la littérature
    Ana Beatriz Pereira de Oliveira, Matthieu Hein · 2026 · L Encéphale
  71. Psychedelic Use Covaries with Psychological Flexibility Through Mystical Experiences: Results of a Retrospective Web Survey
    Angelica Spata, James W. Sturges, Mitch Earleywine · 2026 · Journal of Psychoactive Drugs
  72. Potential Role of Psychedelics in the Treatment of Depressive Disorder
    Sheng‐Min Wang, Won-Myong Bahk · 2026 · Springer eBooks
  73. The Australian Ayahuasca Dietero Networks: Culture, Community, and Practices
    Alana Roy, Martin L Williams, Kimberley Day, Monica Jane Barratt · 2026 · Contemporary Drug Problems
  74. Traces of Medical Concepts in Medieval Islamic Thought: Ibn Sīnā on Melancholy
    Bahar Koca, Manolya Çalışır · 2026 · Cyprus Turkish Journal of Psychiatry and Psychology
  75. From network destabilisation to adaptive reconfiguration: A hippocampal longitudinal axis model of psychedelic therapy
    Charalampos L. Kandilakis, Costas Papatheodoropoulos · 2026 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  76. Ketamine‐Assisted Psychotherapy as an Approach to Psychedelic Healing
    Phil Wolfson · 2026 · Wiley eBooks
  77. Oncology Providers’ Perspectives on Psychedelic-Assisted Therapy
    Krishna S. Hanubal, A. Munjal, Jino Park, R. Banks, Esther Y. Choi, M. Hoyt, Jessi Humphreys, M. Mojtahedzadeh, J. Harris · 2026 · The American journal of hospice & palliative care
  78. Psychedelic-Assisted Therapy
    Maria Laura Mele, Stefano Federici · 2026 · Springer eBooks
  79. Psilocybin-Assisted Therapy for Alcohol Use Disorder: A Systematic Review of Clinical Evidence
    Laura Schäffert, ­Human‐Friedrich Unterrainer · 2026 · Psychoactives
  80. Differential effects of psilocybin derivatives on fentanyl-induced conditioned place preference in male and female mice
    Tiffini N. Lovell, Peter B. James, Skylar L. Hodgins, Samuel Johnson Noya, Patrick Arner, Ana‐Clara Bobadilla · 2026 · Journal of Psychopharmacology
  81. Through the Looking-Glass: A Scoping Review of Psychological Mechanisms of Psychedelic-Assisted Therapy for Substance Use Disorders
    Kathryn Fletcher, Jack Freestone, Nadine Ezard, Elizabeth Knock, Krista J. Siefried · 2026 · Current Addiction Reports
  82. HORMONAL MODULATION OF PSILOCYBIN RESPONSIVITY ACROSS THE FEMALE REPRODUCTIVE LIFESPAN
    Katarzyna Pawłucka, Aleksandra Pawlucka, Joanna Kadłuczka, Makary Hejduk, Magdalena Grzymek, Justyna Bury, Katarzyna Kraska, Jan Potoniec, Weronika Kępa, Aneta Sobek et al. · 2026 · International Journal of Innovative Technologies in Social Science
  83. Exploratory Insights into 5-MeO-DMT Experiences on Reddit: A Thematic Analysis.
    D. Świeczkowski, A. Kwaśny, W. J. Cubała · 2026 · Journal of Psychoactive Drugs
  84. Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review
    Serena Chiara Civardi, Filippo Besana, Federico Durbano, Marco Otto Maria Toscano, F. Raffone, Bernardo Maria Dell’Osso, Miriam Olivola · 2026 · Frontiers in Psychiatry
  85. Psychédéliques et inconscient, quels apports pour la clinique ?
    Laura Di Lodovico · 2026 · Soins Psychiatrie
  86. Designing evaluation infrastructure for psychedelic harm reduction at events: a methodological framework with formative mixed-methods field application
    Nima Veiseh, Francesco Kment, Victor P. Acero, Heather Jackson, Ruth Fisher, Case Newsom, J. Aumick, Armando León, Ishaq Ali, Jessa Hurst et al. · 2026 · Frontiers in Public Health
  87. Moving beyond 5-HT2A: language models map neurotransmitter receptors to experiential semantics
    Praneet Suresh, Josie Kins, Lex Levkovskyy, Andrew Thieme, Paul B. Wren, Tom Ray, Frederick Streeter Barrett, Robin Lester Carhart-Harris, Danilo Bzdok · 2026 · Psychopharmacology
  88. Navigating the Therapeutic Potential of Ego Dissolution
    Rebecka Malm · 2026 · Journal of Anomalous Experience and Cognition
  89. From regulation to practice: A scoping review of prescribers’ roles in psilocybin-assisted therapy
    Gabriel Bélanger, Sue-Ling Chang, Marianne Masse-Grenier, Marie-Joëlle Tremblay, Houman Farzin, Nicolas Garel, Michel Dorval · 2026 · Drug Science Policy and Law
  90. A Narrative Review of Meditation and Psychedelics: Pairing Practices, Synergistic Effects, and a Mutual Research Framework
    Jahred Rosa-Sullivan, Nicholas Cherup, Michael R. Sheehy, Patrick Finian · 2026 · Journal of Contemplative Studies
  91. Ibogaine for Substance Use Disorders
    Ahmed I Anwar, Abdul-rahman A. Hegazi, M. Farris Sawaya, Joshua R. Nelson, Audrey E. Lashley, Jillian M. Gatti, Kristy M Pham, Ibraheem A. Hachem, Molly E. McNulty, Destiny S. Lewis et al. · 2026 · Advances in Therapy
  92. Clarifying “Psychotherapy” and “Psychological Support” in Psychedelic Clinical Trials: The What, the Why and the How
    William Jinwoong Choi · 2026 · Neuroethics
  93. Context Shapes Alpha-Band Electrophysiological Signatures under Psilocybin
    Vidushani Dhanawansa, Devon Stoliker, Leonardo Novelli, Mana Biabani, Adeel Razi, Levin Kuhlmann · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  94. The Serenity Spectrum: Integrating Anxiolytic and Antidepressant Mechanisms for Stress relief
    Harini. M.B, Pinki Verma · 2026 · Asian Journal of Research in Pharmaceutical Sciences
  95. Evaluation of the Effects of Different Doses of Ayahuasca on Intelligence and Verbal Memory in Healthy Volunteers
    Caio César de Paula, Anna Beatriz Vicentini, Lorena Terene Lopes Guerra, Renan Massanobu Maekawa, José Augusto Silva Reis, Bianca Villanova, Caroline C. Gomes, Taini Bellucci, Giordano Novak Rossi, José Carlos Bouso et al. · 2026 · Journal of Clinical Psychopharmacology
  96. Psychoplastogens to Reduce Persistent Cognitive Symptoms for Traumatic Brain Injury as a Chronic Condition
    Hoda K AbouEich, Ali Izadi, Jonathan Lifshitz, David E. Olson, Gene G. Gurkoff · 2026 · Journal of Neurotrauma
  97. Clinical Evidence on Psilocybin and Its Representation in Media Reporting
    Kim Madden, Breanne Flood, Imad Kashir, Rayan Ahmad, Hiba Ali, Rotem Petranker, James MacKillop, Anthony F. Adili · 2026 · JAMA Network Open
  98. Gut consciousness: a perspective on visceral phenomenal awareness
    Gregor Hasler · 2026 · Neuroscience of Consciousness
  99. Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis
    Aline Frick, Grace Blest‐Hopley, Manesh Girn, David Erritzøe, David Nutt, Robin Lester Carhart-Harris · 2026 · Psychopharmacology
  100. BindingDB Entry 50021054: Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists.
    BindingDB · 2025 · UC San Diego